Financials

  • Market Capitalization 11.44 B
  • Employee 3 221
  • Founded N/A
  • CEO Alexander Hardy
  • Website www.biomarin.com
  • Headquarter Delaware, United States
  • FIGI BBG000CZWZ05
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
33.02
Price to sales ratio
3.64

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
823
SMMT
Summit Therapeutics Inc. - Common Stock
15.30 USD+0.33%-4.20%+5.96%-22.96%11.88 B USD
828
AXSM
Axsome Therapeutics, Inc. - Common Stock
228.28 USD-2.36%-5.79%-10.25%+75.33%11.75 B USD
858
TECH
Bio-Techne Corp - Common Stock
71.36 USD+0.08%+0.62%+29.02%+34.67%11.17 B USD
878
KRYS
Krystal Biotech, Inc. - Common Stock
363.44 USD-0.65%-3.21%+14.29%+94.22%10.71 B USD

Frequently asked questions about BioMarin Pharmaceutical Inc. - Common Stock

What is the BioMarin Pharmaceutical Inc. - Common Stock stock price today?

The current price of BioMarin Pharmaceutical Inc. - Common Stock (BMRN) is 59.2. Over the past 24 hours, the stock has changed by +0.14%. Follow the BMRN chart for real-time price dynamics.

What is the stock ticker of BioMarin Pharmaceutical Inc. - Common Stock?

BioMarin Pharmaceutical Inc. - Common Stock trades under the ticker BMRN. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is BioMarin Pharmaceutical Inc. - Common Stock stock going up?

BMRN has changed by -0.74% over the last week, +5.56% over the last month, and +1.02% over the last year. Review the chart to see whether the current move is part of a broader trend.

What was BioMarin Pharmaceutical Inc. - Common Stock net income for the last quarter?

BioMarin Pharmaceutical Inc. - Common Stock reported net income of 105.53 M for the last quarter. The previous quarter showed -46.57 M, which means net income changed by +326.58%.

How many employees does BioMarin Pharmaceutical Inc. - Common Stock have?

As of the latest available data, BioMarin Pharmaceutical Inc. - Common Stock has 3 221 employees. Workforce size can provide additional context about the company's scale and operations.

What is BioMarin Pharmaceutical Inc. - Common Stock EBITDA?

BioMarin Pharmaceutical Inc. - Common Stock EBITDA is 146.05 M, and its EBITDA margin is 19.06%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy BioMarin Pharmaceutical Inc. - Common Stock stock?

You can buy BioMarin Pharmaceutical Inc. - Common Stock (BMRN) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in BioMarin Pharmaceutical Inc. - Common Stock stock?

Investing in BioMarin Pharmaceutical Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the BMRN chart and related analysis on metatrader.com as part of your research.

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.

News